Overview
Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.
Indication
Torasemide is indicated for the treatment of edema associated with congestive heart failure, renal or hepatic diseases. From this condition, it has been observed that torasemide is very effective in cases of kidney failure. As well, torasemide is approved to be used as an antihypertensive agent either alone or in combination with other antihypertensives.
Associated Conditions
- Edema
- Hypertension
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/11/27 | Phase 4 | Terminated | |||
2024/11/01 | Phase 2 | Not yet recruiting | Jemincare | ||
2024/05/14 | Phase 3 | Completed | Ospedale San Raffaele | ||
2024/03/04 | Phase 1 | Completed | |||
2024/02/23 | Phase 4 | Recruiting | National Institute of Cardiology, Warsaw, Poland | ||
2024/01/23 | Phase 4 | Recruiting | |||
2024/01/16 | Phase 2 | Recruiting | |||
2023/09/15 | N/A | Recruiting | China National Center for Cardiovascular Diseases | ||
2023/09/15 | N/A | Recruiting | China National Center for Cardiovascular Diseases | ||
2023/09/14 | N/A | Recruiting | China National Center for Cardiovascular Diseases |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Sarfez Pharmaceuticals Inc | 73502-286 | ORAL | 20 mg in 1 1 | 12/28/2021 | |
| Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 23155-874 | ORAL | 100 mg in 1 1 | 7/17/2023 | |
| Teva Pharmaceuticals USA, Inc. | 50111-915 | ORAL | 5 mg in 1 1 | 2/28/2017 | |
| Carilion Materials Management | 68151-2946 | ORAL | 5 mg in 1 1 | 10/3/2012 | |
| Camber Pharmaceuticals, Inc. | 31722-530 | ORAL | 10 mg in 1 1 | 8/18/2017 | |
| Bryant Ranch Prepack | 63629-1346 | ORAL | 10 mg in 1 1 | 5/23/2023 | |
| Rising Health, LLC | 57237-141 | ORAL | 100 mg in 1 1 | 6/14/2023 | |
| Aurobindo Pharma Limited | 65862-125 | ORAL | 5 mg in 1 1 | 6/14/2023 | |
| Rising Health, LLC | 57237-138 | ORAL | 5 mg in 1 1 | 6/14/2023 | |
| Sarfez Pharmaceuticals Inc | 73502-288 | ORAL | 60 mg in 1 1 | 12/28/2021 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Torasemide Injection | 国药准字H20233411 | 化学药品 | 注射剂 | 5/23/2023 | |
| Torasemide Injection | 国药准字H20040849 | 化学药品 | 注射剂 | 7/30/2020 | |
| Torasemide Injection | 国药准字H20217101 | 化学药品 | 注射剂 | 11/8/2021 | |
| Torasemide Injection | 国药准字H20040847 | 化学药品 | 注射剂 | 7/30/2020 | |
| Torasemide Injection | 国药准字H20243368 | 化学药品 | 注射剂 | 3/19/2024 | |
| Torasemide Injection | 国药准字H20223292 | 化学药品 | 注射剂 | 5/10/2022 | |
| Torasemide Injection | 国药准字H20247068 | 化学药品 | 注射剂 | 4/16/2024 | |
| Torasemide Injection | 国药准字H20223274 | 化学药品 | 注射剂 | 4/29/2022 | |
| Torasemide Injection | 国药准字H20213942 | 化学药品 | 注射剂 | 12/14/2021 | |
| Torasemide Injection | 国药准字H20233412 | 化学药品 | 注射剂 | 5/23/2023 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.